Rein Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Rein Therapeutics, Inc. (RNTX) had Deferred Tax Assets, Operating Loss Carryforwards of $28.68 million as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $28.68M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $17.42M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $12.39M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $64.96M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $28.68M 10-K · filed 2026-03-26 |
| 2024-12-31 | $17.42M 10-K · filed 2026-03-26 |
| 2023-12-31 | $12.39M 10-K · filed 2025-04-07 |
| 2022-12-31 | $64.96M 10-K · filed 2024-04-15 |
| 2021-12-31 | $61.93M 10-K · filed 2023-03-20 |
| 2020-12-31 | $55.23M 10-K · filed 2022-03-28 |
| 2019-12-31 | $50.24M 10-K · filed 2021-03-24 |
| 2018-12-31 | $42.77M 10-K · filed 2020-03-30 |
| 2017-12-31 | $35.16M 10-K · filed 2019-03-29 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-10 |
| 2016-12-31 | $41.95M 10-K · filed 2018-04-02 |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |